Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study

Ueda, Shigeto; Tsuda, Hitoshi; Sendo, Toshiaki; Omata, Jiro; Osaki, Akihiko; Shigekawa, Takashi; Ishida, Jiro; Tamura, Katsumi; Abe, Yoshiyuki; Moriya, Tomoyuki; Yamamoto, Junji

doi:10.1007/s12282-010-0212-y

Cited by 38 publications

(33 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Explanation of exclusion reasons, b e.g., reviews, editorials, guidelines, and perspectives; c e.g., optical imaging and scintimammography; Table 1. Characteristics of studies reporting on mammography, breast ultrasound, MRI, and (17,18,70,87,91,(93)(94)(95)(96)(97)(98)(99)(100)(101)(102)(103)(104)(105)(106)(107). Of these, eight articles reported on two imaging modalities: five on both breast ultrasound and mammography (28,33,41,52,56), and three on both 18 F-FDG PET and DWI (70,87), or MRS (91).…”

Section: Resultsmentioning

confidence: 99%

“…No study included only DCIS, five included invasive cancer and DCIS, and 15 only invasive cancer. Two studies selected on receptor expression: one study only included ER-positive breast cancer (106), and one excluded patients with HER2-positive disease who received trastuzumab within a neoadjuvant setting (97). All studies used whole-body PET or PET/CT, except one that used dedicated positron emission mammography (PEM; …”

Section: F-fdg Uptake In Relation To Her2 Overexpression In Breast Camentioning

confidence: 99%

See 1 more Smart Citation

Imaging Features of HER2 Overexpression in Breast Cancer: A Systematic Review and Meta-analysis

Elias

Adams

Wisner

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Breast cancer imaging phenotype is diverse and may relate to molecular alterations driving cancer behavior. We systematically reviewed and meta-analyzed relations between breast cancer imaging features and human epidermal growth factor receptor type 2 (HER2) overexpression as a marker of breast cancer aggressiveness. MEDLINE and EMBASE were searched for mammography, breast ultrasound, magnetic resonance imaging (MRI), and/or [ 18 F]fluorodeoxyglucose positron emission tomography studies through February 2013. Of 68 imaging features that could be pooled (85 articles, 23,255 cancers; random-effects meta-analysis), 11 significantly related to HER2 overexpression. Results based on five or more studies and robustness in subgroup analyses were as follows: the presence of microcalcifications on mammography [pooled odds ratio (pOR), 3.14; 95% confidence interval (CI), 2.46-4.00] or ultrasound (mass-associated pOR, 2.95; 95% CI, 2.34-3.71), branching or fine linear microcalcifications (pOR, 2.11; 95% CI, 1.07-4.14) or extremely dense breasts on mammography (pOR, 1.37; 95% CI, 1.07-1.76), and washout (pOR, 1.57; 95% CI, 1.11-2.21) or fast initial kinetics (pOR, 2.60; 95% CI, 1.43-4.73) on MRI all increased the chance of HER2 overexpression. Maximum [ 18 F]fluorodeoxyglucose standardized uptake value (SUV max ) was higher upon HER2 overexpression (pooled mean difference, þ0.76; 95% CI, 0.10-1.42). These results show that several imaging features relate to HER2 overexpression, lending credibility to the hypothesis that imaging phenotype reflects cancer behavior. This implies prognostic relevance, which is especially relevant as imaging is readily available during diagnostic work-up. Cancer Epidemiol Biomarkers Prev; 23(8); 1464-83. Ó2014 AACR.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: F-fdg Uptake In Relation To Her2 Overexpression In Breast Camentioning

confidence: 99%

Imaging Features of HER2 Overexpression in Breast Cancer: A Systematic Review and Meta-analysis

Elias

Adams

Wisner

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…currently evaluated [26,27]. An alternative to evaluate the presence of viable tumor cells is by measuring the readily available immunohistochemical analysis of the nuclear antigen Ki67 [28].…”

Section: Discussionmentioning

confidence: 99%

Response prediction to neoadjuvant chemotherapy: Comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay.

Singer¹,

Klinglmüller²,

Staudigl³

et al. 2010

JCO

View full text Add to dashboard Cite

Although the use of (neo-)adjuvant chemotherapy in breast cancer patients has resulted in improved outcome, not all patients benefit equally. We have evaluated the utility of an in vitro chemosensitivity assay in predicting response to neoadjuvant chemotherapy. Pre-therapeutic biopsies were obtained from 30 breast cancer patients assigned to neoadjuvant epirubicin 75 mg/m2 and docetaxel 75 mg/m2 (Epi/Doc) in a prospectively randomized clinical trial. Biopsies were subjected to a standardized ATP-based Epi/Doc chemosensitivity assay, and to gene expression profiling. Patients then received 3 cycles of chemotherapy, and response was evaluated by changes in tumor diameter and Ki67 expression. The efficacy of Epi/Doc in vitro was correlated with differential changes in tumor cell proliferation in response to Epi/Doc in vivo (p = 0.0011; r = 0.73670, Spearmans rho), but did not predict for changes in tumor size. While a pre-therapeutic gene expression signature identified tumors with a clinical response to Epi/Doc, no such signature could be found for tumors that responded to Epi/Doc in vitro, or tumors in which Epi/Doc exerted an antiproliferative effect in vivo. This is the first prospective clinical trial to demonstrate the utility of a standardized in vitro chemosensitivity assay in predicting the individual biological response to chemotherapy in breast cancer.

show abstract

“…Successful cytostatic drugs include ER antagonists such as tamoxifen, which induce the deprivation of estrogen production, aromatase inhibitors, ER downregulators, or fulvestrant. In 2011, we reported that changes in SUV at approximately 2 weeks after treatment with letrozole, an aromatase inhibitor, was correlated with a drop in proliferative rate of cancer cells measured by immunohistochemical staining of Ki67 [47]. With a tentative threshold value of a 40% decrease in SUV, Ki67 index values were significantly decreased in metabolic responders.…”

Section: Early Changes In Metabolism Using Molecular-targeted Drugs Amentioning

confidence: 99%

Early Prediction of Tumor Response: A Future Strategy for Optimizing Cancer Treatment

Ueda¹,

Sendo²

2013

Positron Emission Tomography - Recent Developments in Instrumentation, Research and Clinical Oncological Practice

Self Cite

View full text Add to dashboard Cite

Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study

Abstract: Cell-cycle response monitored by the Ki67 labeling index correlates with metabolic response monitored by tumor SUV(max). Monitoring of tumor SUV(max) using FDG PET/CT may be feasible to predict cell-cycle response to neoadjuvant endocrine therapy of primary breast cancer.

Cited by 38 publications

References 26 publications

Imaging Features of HER2 Overexpression in Breast Cancer: A Systematic Review and Meta-analysis

Imaging Features of HER2 Overexpression in Breast Cancer: A Systematic Review and Meta-analysis

Response prediction to neoadjuvant chemotherapy: Comparison between pretherapeutic gene expression profiles and in vitro chemosensitivity assay.

Early Prediction of Tumor Response: A Future Strategy for Optimizing Cancer Treatment

Contact Info

Product

Resources

About